[go: up one dir, main page]

CL2013003556A1 - Compuestos derivados de ftalazinona-pirrolo[3,2-d]pirimidin-carboxamida, inhibidoers de fosfodiesterasa tipo 4 y tipo 5; composcin farmaceutica que o comprende, combinacion fija, no fija y kit, uso del compuesto en la preparacion de un medicamento para trata enfermedaes de las vias respiratorias - Google Patents

Compuestos derivados de ftalazinona-pirrolo[3,2-d]pirimidin-carboxamida, inhibidoers de fosfodiesterasa tipo 4 y tipo 5; composcin farmaceutica que o comprende, combinacion fija, no fija y kit, uso del compuesto en la preparacion de un medicamento para trata enfermedaes de las vias respiratorias

Info

Publication number
CL2013003556A1
CL2013003556A1 CL2013003556A CL2013003556A CL2013003556A1 CL 2013003556 A1 CL2013003556 A1 CL 2013003556A1 CL 2013003556 A CL2013003556 A CL 2013003556A CL 2013003556 A CL2013003556 A CL 2013003556A CL 2013003556 A1 CL2013003556 A1 CL 2013003556A1
Authority
CL
Chile
Prior art keywords
type
fixed
phthalazinone
pyrrolo
pyrimidine
Prior art date
Application number
CL2013003556A
Other languages
English (en)
Inventor
Thomas Stengel
Thomas Maier
Alexander Mann
Josef Stadlwieser
Dieter Flockerzi
Andreas Pahl
Ewald Benediktus
Manuela Hessmann
Tobias Kanacher
Ragna Hussong
Christof Zitt
Hans Christof Holst
Rolf Peter Hummel
Martin Viertelhaus
Hermann Tenor
Torsten Dunkern
Armin Hatzelmann
Christian Hesslinger
Original Assignee
Takeda Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44764312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013003556(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Gmbh filed Critical Takeda Gmbh
Publication of CL2013003556A1 publication Critical patent/CL2013003556A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2013003556A 2011-06-17 2013-12-11 Compuestos derivados de ftalazinona-pirrolo[3,2-d]pirimidin-carboxamida, inhibidoers de fosfodiesterasa tipo 4 y tipo 5; composcin farmaceutica que o comprende, combinacion fija, no fija y kit, uso del compuesto en la preparacion de un medicamento para trata enfermedaes de las vias respiratorias CL2013003556A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11170440 2011-06-17

Publications (1)

Publication Number Publication Date
CL2013003556A1 true CL2013003556A1 (es) 2014-06-13

Family

ID=44764312

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013003556A CL2013003556A1 (es) 2011-06-17 2013-12-11 Compuestos derivados de ftalazinona-pirrolo[3,2-d]pirimidin-carboxamida, inhibidoers de fosfodiesterasa tipo 4 y tipo 5; composcin farmaceutica que o comprende, combinacion fija, no fija y kit, uso del compuesto en la preparacion de un medicamento para trata enfermedaes de las vias respiratorias

Country Status (22)

Country Link
US (2) US20140112945A1 (es)
EP (1) EP2721030B1 (es)
JP (1) JP5980318B2 (es)
KR (1) KR20140037195A (es)
CN (1) CN103582644B (es)
AR (1) AR086915A1 (es)
AU (1) AU2012269133A1 (es)
BR (1) BR112013031791A2 (es)
CA (1) CA2837248A1 (es)
CL (1) CL2013003556A1 (es)
CO (1) CO6852074A2 (es)
CR (1) CR20130656A (es)
DO (1) DOP2013000298A (es)
EA (1) EA023713B1 (es)
EC (1) ECSP13013076A (es)
ES (1) ES2564882T3 (es)
MA (1) MA35269B1 (es)
MX (1) MX2013014888A (es)
PE (1) PE20140648A1 (es)
PH (1) PH12013502546A1 (es)
TN (1) TN2013000439A1 (es)
WO (1) WO2012171900A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3209313B1 (en) 2015-04-09 2018-12-19 Galderma SA An extract from indigo naturalis and a process for preparing the same
WO2016162488A1 (en) * 2015-04-09 2016-10-13 Galderma Sa Treatment of atopic dermatitis with indigo naturalis or indigo producing plant extract
BR112017021190B1 (pt) 2015-04-09 2021-12-21 Galderma Sa. Uso de uma composição farmacêutica que compreende um extrato de indigo naturalis
WO2016162490A1 (en) 2015-04-09 2016-10-13 Galderma Sa Antibacterial indigo naturalis or indigo-producing plant extract and use thereof
US12383547B2 (en) 2020-07-01 2025-08-12 Vanderbilt University Methods of treatment for a kidney disease

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
DK0407028T4 (da) 1989-05-31 2000-01-31 Fisons Plc Anordning til inhalation af medikamenter og sammensætning af medikamenter
GB8921222D0 (en) 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
IE67185B1 (en) 1990-02-02 1996-03-06 Fisons Plc Propellant compositions
DE4003272A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
WO1991014422A1 (en) 1990-03-23 1991-10-03 Minnesota Mining And Manufacturing Company The use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
WO1992006675A1 (en) 1990-10-18 1992-04-30 Minnesota Mining And Manufacturing Company Aerosol formulation comprising beclomethasone 17,21 dipropionate
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
GB9213874D0 (en) 1992-06-30 1992-08-12 Fisons Plc Process to novel medicament form
GB9306703D0 (en) 1993-03-31 1993-05-26 Fisons Plc Inhalation device
IL111194A (en) 1993-10-08 1998-02-08 Fisons Plc Process for the production of medicament formulations
DE69811645T2 (de) * 1997-01-15 2003-12-04 Altana Pharma Ag Phtalazinonen
ATE270278T1 (de) * 1998-03-14 2004-07-15 Altana Pharma Ag Phthalazinone pde iii/iv hemmer
WO2000007567A1 (de) 1998-08-04 2000-02-17 Jago Research Ag Medizinische aerosolformulierungen
US6397838B1 (en) 1998-12-23 2002-06-04 Battelle Pulmonary Therapeutics, Inc. Pulmonary aerosol delivery device and method
BR0009993A (pt) 1999-04-23 2002-01-08 Battelle Memorial Institute Pulverizador de aerossol eletrohidrodinâmico direcionalmente controlado, dispositivo para liberar gotìculas de aerossol eletricamente neutras, aparelho para liberar gotìculas de aerossol terapêuticas, processo para liberar gotìculas de aerossol, e, dispositivo para liberar aerossol
WO2000064591A1 (en) 1999-04-23 2000-11-02 Battelle Memorial Institute High mass transfer electrosprayer
PL358057A1 (en) * 2000-06-05 2004-08-09 Altana Pharma Ag Compounds effective as beta-2-adrenoreceptor agonists as well as pde4-inhibitors
CA2425035A1 (en) 2000-10-09 2002-04-18 3M Innovative Properties Company Medicinal aerosol formulations
JP4301812B2 (ja) * 2001-02-15 2009-07-22 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅ４インヒビターとしてのフタラインオン−ピペリジノ−誘導体
AU2002317733B2 (en) 2001-04-25 2007-12-13 Altana Pharma Ag Phthalazinones derivatives useful as PDE4/7 inhibitors
CA2494650A1 (en) * 2002-08-10 2004-03-04 Altana Pharma Ag Pyridazinone-derivatives as pde4 inhibitors
WO2004017974A1 (en) 2002-08-10 2004-03-04 Altana Pharma Ag Piperidine-pyridazones and phthalazones as pde4 inhibitors
WO2004018449A1 (en) 2002-08-10 2004-03-04 Altana Pharma Ag Piperidine-derivatives as pde4 inhibitors
HRP20050699A2 (en) * 2003-01-14 2006-11-30 Altana Pharma Ag Pde4 inhibitors for the treatment of neoplasms of lymphoid cells
CA2554797C (en) 2004-02-04 2012-09-04 Altana Pharma Ag 2-(piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-one derivatives as pde4 inhibitors
EP1720854A1 (en) 2004-02-04 2006-11-15 Altana Pharma AG Phthalzinone derivatives as pde4 inhibitors
AR070454A1 (es) * 2008-02-27 2010-04-07 Nycomed Gmbh Pirrolopirimidincarboxamidas y composiciones farmaceuticas que las comprenden
AR077898A1 (es) * 2009-08-26 2011-09-28 Nycomed Gmbh Metilpirrolopirimidincarboxamidas

Also Published As

Publication number Publication date
US20160108049A1 (en) 2016-04-21
TN2013000439A1 (en) 2015-03-30
CN103582644A (zh) 2014-02-12
JP2014517021A (ja) 2014-07-17
US20140112945A1 (en) 2014-04-24
DOP2013000298A (es) 2014-03-31
CO6852074A2 (es) 2014-01-30
CR20130656A (es) 2014-02-18
CN103582644B (zh) 2016-07-20
KR20140037195A (ko) 2014-03-26
EA201400001A1 (ru) 2014-05-30
WO2012171900A1 (en) 2012-12-20
AR086915A1 (es) 2014-01-29
ES2564882T3 (es) 2016-03-29
EP2721030B1 (en) 2015-12-16
MA35269B1 (fr) 2014-07-03
MX2013014888A (es) 2014-02-27
JP5980318B2 (ja) 2016-08-31
EA023713B1 (ru) 2016-07-29
CA2837248A1 (en) 2012-12-20
AU2012269133A1 (en) 2014-01-30
BR112013031791A2 (pt) 2017-01-31
ECSP13013076A (es) 2014-01-31
PH12013502546A1 (en) 2014-01-27
EP2721030A1 (en) 2014-04-23
PE20140648A1 (es) 2014-05-30

Similar Documents

Publication Publication Date Title
BR112015003332A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015008365A2 (pt) composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente
BR112015003398A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
HUE053113T2 (hu) Bardoxolon-metil 2,2-difluorpropionamid-származéka, annak gyógyszerkészítményei és polimorfjai bizonyos betegségek kezelésében történõ alkalmazásra
IL231226A (en) Compounds and preparations as kinase c-kit inhibitors, pharmaceutical preparations containing them and their use in the preparation of medicines for the treatment of diseases
BR112014010177A2 (pt) composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
BR112014010206A2 (pt) composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
SV2011003939A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
CL2012003632A1 (es) Compuestos derivados de pirazolo[1,5-a]pirimidinas o una sal farmaceuticamente aceptable de los mismos; composicion farmaceutica que los comprende; y su uso para tratar una infeccion por virus pneumovirinae o una infeccion por virus sincicial respiratorio.
CL2014001158A1 (es) Compuestos derivados de piperazina alquilados; composicion farmaceutica que los comprende; proceso para preparar la composicion farmaceutica; kit y uso en el tratamiento de trastornos inmunes, cancer, enfermedades cardiovasculares, inflamacion, entre otros.
IL232267A (en) Derivatives of (4-phenylimidazole-2-ram) ethylamine, pharmaceuticals containing them used to treat them in diseases where sodium channel inhibition nav 1.8 is effective
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
CL2013003051A1 (es) Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
IL231536A (en) Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
IL216741A (en) History of imidazolidine-2-van 1,3-imaging modalities as 17-cyp inhibitors, pharmaceutical preparations containing them, and their use in the preparation of drugs for the treatment of diseases
BR112014011671A2 (pt) composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto
ZA201000075B (en) Purin derivatives for use in the treatment of fab-related diseases
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
CL2013002177A1 (es) Compuestos derivados de 9h-purinas y 7h-pirrolo[2,3-d]-pirimidinas sustituidas, inhibidores de la pi3k de clase i y/o mtor; su composicon farmaceutica; su combinacion farmaceutica; y su uso en el tratamiento o la prevencion del cancer o trastornos neurodegenerativos.
HUE043540T2 (hu) Szubsztituált dimer kinazolin-származék, elõállítása, valamint alkalmazása 1-es és 2-es típusú cukorbetegség kezelésére szolgáló gyógyászati készítményekben
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
CL2014001047A1 (es) Compuestos heterociclicos derivados de pirazina; composicion y combinacion farmaceutica que los contienen y el uso en enfermedades respiratorias y alergicas.